GLP-1 Medications in Addiction Treatment

A New Tool in Addiction Medicine

GLP-1 receptor agonists — medications like semaglutide, liraglutide, and tirzepatide, developed originally for diabetes and obesity — are emerging as one of the most interesting developments in addiction medicine in years. A growing body of research, including large-scale clinical studies, indicates that these medications reduce craving and substance use across multiple classes of addiction: alcohol, opioids, stimulants, nicotine, and cannabis. The evidence base is still developing, and I find it compelling but not yet settled. But what is already emerging is strong enough that where craving is a persistent, significant problem, withholding these medications would be its own clinical failure.

How I Use Them

I prescribe GLP-1 medications in my practice as one tool among several — not as a replacement for the broader work of treatment, but as a way of creating neurological conditions that make that work more possible. The parallel to other medications I use is direct: Suboxone stabilizes the opioid system so a person can think clearly and engage in treatment; a benzodiazepine taper restabilizes the neurological system it disrupted. GLP-1 medications appear to modulate the reward system in a way that may reduce the compulsive drive that makes addiction so difficult to interrupt.

The medication does not do the work. It creates conditions under which the work — the ongoing conversation about what has been driving the addiction, what the substance or behavior has been managing, what has never been examined — becomes accessible. That has always been the role of medication in this practice.

The evidence is most established in compulsive overeating and obesity, and it is from that model that the broader application to other addictions is being extrapolated. That extrapolation is serious — the neurobiology is coherent, the early data are encouraging, and craving that persists despite everything else is a genuine clinical problem and deserves to be treated as one. Where craving remains a significant obstacle despite other interventions, I consider GLP-1 medications carefully, as a tool that may make a meaningful difference — not as an established answer.

How They Work

GLP-1 is a hormone produced in the gut and in a small population of neurons in the brainstem. Its receptors are expressed not only in the pancreas and gastrointestinal tract but in brain regions central to addiction — the circuitry that drives craving, compulsive use, and the inability to stop despite consequences.

GLP-1 medications, by acting on these receptors, appear to modulate dopamine signaling in ways that may reduce the intensity of craving itself — not against any single substance specifically, but against the reward-seeking drive that underlies addiction broadly. Patients describe this as a quieting: the constant preoccupation with the substance or behavior loses its urgency. The pull is still there, but it is no longer overwhelming. The capacity to choose — genuinely choose — begins to return.

What the Evidence Shows

Research in this area is moving rapidly, and the type of evidence currently available matters. Large population-level studies involving hundreds of thousands of patients have found that GLP-1 medication use is associated with significant reductions in the risk of developing substance use disorders across every major substance class — alcohol, opioids, cocaine, cannabis, and nicotine. Among people with existing substance use disorders, GLP-1 use has been associated with substantial reductions in emergency department visits, hospitalizations, overdoses, and drug-related deaths. These are associations, not yet the results of large controlled clinical trials — a distinction that matters scientifically, even as the pattern across multiple studies is striking.

Clinical trials are now underway specifically examining GLP-1 medications in the treatment of alcohol use disorder, opioid use disorder, cocaine use disorder, and others. Preliminary results have been encouraging, including reductions in alcohol consumption, reduced opioid craving, and extended periods without use. This is a rapidly evolving area of research, and the picture will become clearer over the next few years.

Frequently Asked Questions

Q: What are the side effects?

A: The most common side effects are gastrointestinal — nausea, vomiting, constipation, and diarrhea. Most of these are dose-dependent, and nearly all of them arise from escalating the dose too quickly. I titrate slowly and deliberately, with the goal of finding the minimum dose that achieves the clinical effect we are looking for — this is how side effects are avoided, not merely managed after the fact. More significant side effects are less common but exist, and are discussed before starting and monitored throughout.

Q: How are GLP-1 medications taken?

A: They are available in both subcutaneous injection and oral formulations. Which one is right for a particular person depends on their preference and the clinical picture.

Q: Are these medications used alone or alongside other treatment?

A: For compulsive overeating, GLP-1 medications are typically the primary medication, though others may also be considered depending on the clinical picture. For other addictions, they are generally used alongside other medications and treatment rather than as a standalone intervention. In all cases, medication is one part of a broader effort to understand what has been driving the problem — not a substitute for that work.

Q: How long do patients take these medications?

A: For as long as they are helpful. The goal of treatment in this practice is always eventual discontinuation of medication — not indefinite management. How quickly that becomes possible depends on how the broader work progresses, and varies considerably from person to person.

Q: How much do these medications cost?

A: GLP-1 medications are expensive and not reliably covered by insurance. This is a practical reality that factors into whether they are the right choice for a given person.

Q: Do I need to have tried other treatments before being considered for GLP-1 medications?

A: No. Anyone for whom craving is a significant clinical problem and who does not have a contraindication to their use is a potential candidate. Where they fit in the overall treatment picture is determined individually.

Q: Is this just a weight loss drug being repurposed?

A: No. GLP-1 medications act directly on brain regions central to addiction. The convergence of preclinical research, large-scale population-level data, early clinical trials, and consistent clinical experience of reduced craving across substance classes makes this a pharmacological intervention with genuine relevance to addiction medicine — not a repurposed diet drug.

Getting in Touch

The first conversation is free and completely confidential. There is no obligation of any kind.

Call directly: (646) 418-7077